Alembic Pharma Expects 20-25% Revenue Growth In FY27, Says CFO G Krishnan

Alembic Pharmaceuticals expects to sustain strong revenue growth in FY27, with consolidated growth projected in the 20-25% range, CFO G Krishnan told NDTV Profit. The company expects EBITDA margins to remain in the high teens for the full year, while its US business is set to continue growing, supported by new product launches and growth opportunities. Krishnan said the company expects bosutinib exclusivity to expand its US market presence, with more product launches planned in the region. The outlook comes amid strong momentum in the company's US generics business.